European Commission approves obiltoxaximab for the treatment of inhalation anthrax.- Elusys Therapeutics

Elusys Therapeutics, Inc. announced that the European Commission has approved obiltoxaximab, the company’s monoclonal antibody (mAb) anthrax antitoxin for the treatment of inhalation anthrax. Obiltoxaximab is indicated in all age groups in combination with appropriate antibacterial drugs for the treatment of inhalational anthrax due to Bacillus anthracis; and for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not available or not appropriate. This EU approval for obiltoxaximab will be automatically converted to a UK marketing authorization on January 1, 2021. SFL Pharmaceuticals Deutschland GmbH (SFL Pharmaceuticals) will act as marketing authorization holder (MAH) in the EU and the UK on behalf of Elusys, the originator of the product.